ACTRN12623000577617尚未招募Unknown
Safety, tolerability and pharmacokinetics of subcutaneous meropenem and cefazolin as an alternative to intravenous delivery in adults
aurens Manning0 个研究点目标入组 60 人开始时间: 2023年5月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •18 years of age or over.
- •Inpatient who is clinically stable, defined as not having been in ICU or having had an emergency response call in the 24 hours prior to enrolment.
- •Ability to provide informed consent.
- •Patient must be receiving = 1g of meropenem or = 2g cefazolin daily.
- •Anticipated to require IV cefazolin or meropenem for at least 48 hours after enrolment.
排除标准
- •Patients not clinically stable, as defined by being in ICU, having had a MET call in the 24 hours before screening for enrolment.
- •Children <18 years
- •Patients whose treating team predict will cease meropenem within 48 hours.
- •Patients receiving >1g meropenem, or >2g cefazolin per dosing interval.
- •Patients also taking medications predicted to interfere with meropenem or cefazolin pharmacokinetics (valproic acid, probenecid)
- •Patients unable to give informed consent themselves.
研究者
相似试验
已完成
1 期
Study to find out if the drug Vessel Dilator” is absorbed from an injection under the skin and, whether it improves heart function in people diagnosed with chronic heart failure and a moderate degree of kidney function loss.Chronic Heart FailureRenal ImpairmentCardiovascular - Other cardiovascular diseasesRenal and Urogenital - Other renal and urogenital disordersACTRN12611000806965Madeleine Pharmaceuticals Pty Ltd8
招募中
4 期
Safety, tolerability and pharmacokinetics of 2g subcutaneous ceftriaxone as an alternative to intravenous administratioInfectionInfection - Other infectious diseasesInfection - Studies of infection and infectious agentsACTRN12624000692538Fiona Stanley Hospital24
尚未招募
2 期
IVERSAL2: Pharmacokinetics safety and acceptability of DRV/r for children living with HIVHIV/AIDSPACTR202405769820746Fondazione Penta ETS50
暂停
1 期
A study in healthy Japanese men to test how different doses of BI 894416 are toleratedJPRN-jRCT2080225328ippon Boehringer Ingelheim Co., Ltd.24
招募中
1 期
A study in healthy Japanese men to test how well different dosesof BI 1569912 are toleratedMajor Dipressive DisorderJPRN-jRCT2071210037Furuichi Takumi44